Biogen (BIIB) Hisse Fiyat
Biogen Fiyat
Gelir, son 19 yılda yıllık bileşik %7,1 artarak 9,89 Md USD seviyesine ulaştı. Hisse başına kâr, son 19 yılda yıllık %14,9 büyüdü. Biogen şirketinde net marj %13,1 seviyesinde bulunuyor; birkaç yıl önceki %14,2 seviyesine göre geriledi. Analistler 240,00 USD medyan fiyat hedefi belirliyor; bu, güncel fiyatın %1,7 üzerinde bir seviyeye işaret ediyor. 43 analistten 30 tanesi hisse için alım öneriyor — genel konsensüs: Al.
Biogen hisse senedi fiyatı
Bu verilere Eulerpool API üzerinden ulaşın
Ayda 100.000 ücretsiz istek · kredi kartı yok
Biogen iş modeli ve hisse analizi
Biogen hakkında sık sorulan sorular
Biogen Inc.'s business model revolves around the development, manufacturing, and commercialization of therapies for neurological, autoimmune, and rare diseases. As a leading biotechnology company, Biogen focuses on creating innovative treatments to address unmet medical needs. With a diverse portfolio encompassing multiple therapeutic areas, including multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease, Biogen strives to improve patients' lives worldwide. Through strategic collaborations and scientific advancements, the company continues to invest in cutting-edge research and development to bring transformative therapies to patients, making Biogen a key player in the biopharmaceutical industry.
Biogen Inc is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of Biogen Inc in the market are Amgen Inc, AbbVie Inc, and Gilead Sciences Inc.
Biogen Inc is a renowned biotechnology company with a rich history and impressive background. Founded in 1978, Biogen has consistently aimed to develop innovative therapies for patients facing serious neurological and neurodegenerative diseases. Over the years, the company has made significant contributions to the field of biotechnology, especially in areas like multiple sclerosis (MS) and spinal muscular atrophy (SMA). Biogen's mission involves relentless pursuit of scientific excellence and commitment to improving patients' lives. With a diverse portfolio of groundbreaking therapies and a global presence, Biogen continues to be a leading player in the biotechnology industry, dedicated to transforming the course of human health.
Biogen Inc, a leading biotechnology company, has achieved several significant milestones. Notably, the company successfully introduced the first treatment for multiple sclerosis, revolutionizing the lives of patients worldwide. Biogen also developed ground-breaking therapies for spinal muscular atrophy, empowering patients with this rare genetic disease. Moreover, the company made strides in neurology and introduced medications addressing Alzheimer's disease and Parkinson's disease. Biogen's commitment to innovation has led to these remarkable achievements, positioning the company as a pioneer in the biotech industry. As an influential player, Biogen Inc continues to drive advancements in healthcare, improving the quality of life for countless individuals.
Biogen Inc operates in several countries and regions around the world. As a leading biotechnology company, Biogen Inc has a significant presence in the United States, where it is headquartered. Additionally, Biogen Inc has operations and presence in Europe, including countries such as Germany, France, Italy, and Switzerland. The company also serves markets in Asia, with a presence in Japan, South Korea, and several other countries in the region. Biogen Inc's global footprint allows it to reach a wide range of patients and healthcare providers, ensuring its innovative therapies and treatments are accessible to individuals in various parts of the world.
Biogen Inc is a biotechnology company known for its commitment to scientific innovation and improving patients' lives. Guided by their corporate philosophy, Biogen Inc strives to discover, develop, and deliver innovative therapies for neurological, autoimmune, and rare diseases. The company values integrity, diversity, and inclusion in their pursuit of breakthrough treatments, always putting patients at the forefront. Biogen Inc's collaborative approach, dedication to scientific rigor, and passion for making a difference have earned it a leading position in the biotech industry. With a focus on transformative therapies, Biogen Inc continues to drive advancements in healthcare and empower patients worldwide.
Analistler şu anda Biogen hissesi için ortalama 238,69 USD hedef fiyat belirliyor (medyan: 240,00 USD); bu, son fiyata göre +1,1 % anlamına gelir. Konsensüs 43 analist notuna dayanır.
43 analist şu anda Biogen hissesini değerlendiriyor: 30 al, 12 tut, 1 sat öneriyor. 2026 için analistler Biogen şirketinin 10,45 Md USD gelir ve 12,42 USD hisse başına kâr üretmesini bekliyor.
Güncel döviz kuruyla Biogen hissesi 209,95 EUR (236,00 USD) seviyesindedir.
Biogen hissesi (BIIB) 11 borsada işlem görür, bunlar arasında: NASDAQ (BIIB), London (0R1B.L), SIX (Zürich) (BIIB.SW), XETRA (IDP.DE), Frankfurt (IDP.F), München (IDP.MU), Düsseldorf (IDP.DU), Hamburg (IDP.HM).
Biogen Inc. is a biopharmaceutical company specializing in the research, development, and marketing of therapies for neurological, hematological, and autoimmune diseases. It was founded in 1978 and is headquartered in Cambridge, Massachusetts. Biogen currently has three main business segments: Neurology, Hematology, and Biosimilars. The Neurology division focuses on the development and marketing of drugs for the treatment of Multiple Sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA), and other neurological disorders. The Hematology division focuses on the development of therapies for blood diseases such as Hemophilia and Sickle Cell Anemia. The Biosimilars division focuses on the development of generic versions of biological drugs. Biogen has partnerships with other major companies such as Eisai Co. and Ionis Pharmaceuticals to work on the development of new drugs and therapies. The company's business model is based on the sale of patented drugs and the development of new therapies. In summary, Biogen is a biopharmaceutical company specializing in the development and marketing of therapies for neurological, hematological, and autoimmune diseases, aiming to improve the lives of patients worldwide.
beklenen'nin Biogen hasılatı 10,45 Md USD'dir. Bu rakam, mevcut finansal verilere dayanmakta ve şirketin iş performansını yansıtmaktadır.
beklenen'nin Biogen karı 1,83 Md USD'dir. Net kar, tüm giderleri düştükten sonra şirketin kârlılığını gösterir.
Biogen'nin Fiyat/Kazanç (F/K) oranı şu anda 19,00'dir. F/K oranı, cari hisse fiyatını hisse başına kazançla karşılaştırır ve yatırımcıların Biogen hisse senedinin değerlemesini değerlendirmelerine yardımcı olur.
Biogen'nin Fiyat/Satış (F/S) oranı şu anda 3,32'dir. F/S oranı, pazar kapitalizasyonunu yıllık gelirle karşılaştırır ve Biogen hisse senedinin değerleme metriği olarak hizmet eder.
Biogen'nin Eulerpool Kalite Puanı 3/10'dur.
Biogen'nin ISIN'i US09062X1037'dir. ISIN (Uluslararası Menkul Kıymetler Kimlik Numarası), menkul kıymetler için küresel olarak benzersiz bir tanımlayıcıdır.
Biogen'nin WKN'i 789617'dir. WKN (Wertpapierkennnummer), menkul kıymetleri tanımlamak için kullanılan altı haneli bir Alman kimlik numarasıdır.
Biogen'nin ticker'ı BIIB'dir. Ticker sembolü, Biogen hisseleri borsada işlem görmek için kullanılır.
Biogen Hissesi
Biogen Emsaller Grubu
Biogen Ticker
Biogen FIGI
Biogen'nin tüm temel göstergeleri ve derinlemesine analizi
Biogen hissesine yönelik aktienanalizimiz, satış, kar, P/E oranı, P/S oranı, EBIT gibi önemli mali kriterleri içermekte olup, dividende bilgilerini de ele almaktadır. Ayrıca, hisseler, piyasa değeri, borçlar, özsermaye ve Biogen şirketin yükümlülükleri gibi konuları incelemekteyiz. Bu konular hakkında daha detaylı bilgilere ihtiyacınız varsa, web sitemizin alt sayfalarında kapsamlı analizler sunuyoruz: